急性卒中患者接受静脉降压药物输注时血压与心率相关变量的评估
该研究基于MIMIC-IV重症监护数据库,分析1830例接受静脉降压治疗(克莱维地平64例、尼卡地平1623例、硝普钠143例)的急性卒中患者,探讨治疗前后收缩压与心率相关变量与院内死亡及急性肾损伤的关系。结果显示死亡患者治疗前收缩压标准差(16.3 vs 13.7,p≤0.001)和治疗后收缩压标准差(15.4 vs 14.4,p=0.004)均高于存活者,尤其在脑出血患者中。三种药物均显著降低平均收缩压,但未降低收缩压波动。作者认为需优化治疗干预以减少急性卒中患者的收缩压波动。
要点
- 死亡患者治疗前收缩压标准差16.3 vs 存活者13.7(p≤0.001),治疗后15.4 vs 14.4(p=0.004),收缩压波动与院内死亡相关。
- 克莱维地平、尼卡地平、硝普钠均显著降低平均收缩压,但均未降低治疗后收缩压标准差。
- 脑出血患者接受尼卡地平治疗后收缩压标准差显著升高(13.1 vs 14.2,p=0.0032)。
- 缺血性卒中及脑出血接受克莱维地平或硝普钠者,治疗前后收缩压标准差无显著差异。
适用人群与场景
- 急性卒中并接受静脉降压药物输注的成人重症监护患者,数据来自MIMIC-IV数据库。
- 药物包括静脉克莱维地平(n=64)、尼卡地平(n=1623)或硝普钠(n=143)。
处置流程与药物剂量
- 静脉克莱维地平治疗后平均收缩压130.7 mm Hg vs 治疗前142.5 mm Hg(p=0.006)。
- 静脉尼卡地平治疗后平均收缩压132.8 mm Hg vs 治疗前141.6 mm Hg(p≤0.001)。
- 静脉硝普钠治疗后平均收缩压126.2 mm Hg vs 治疗前139.6 mm Hg(p≤0.001)。
研究设计与关键结果
- 研究类型为基于MIMIC-IV电子数据库的分析,共纳入1830例急性卒中患者接受静脉克莱维地平(n=64)、尼卡地平(n=1623)或硝普钠(n=143)治疗。
- 死亡患者治疗前收缩压标准差16.3 vs 存活者13.7(p≤0.001),治疗后收缩压标准差15.4 vs 14.4(p=0.004),尤其在脑出血患者中。
- 治疗后平均收缩压较治疗前显著降低:克莱维地平130.7 vs 142.5 mm Hg(p=0.006),尼卡地平132.8 vs 141.6 mm Hg(p≤0.001),硝普钠126.2 vs 139.6 mm Hg(p≤0.001)。
- 治疗前后平均收缩压标准差无差异:克莱维地平14.5 vs 13.5(p=0.407),尼卡地平14.2 vs 14.6(p=0.142),硝普钠14.8 vs 14.8(p=0.997)。
- 缺血性卒中接受克莱维地平、尼卡地平或硝普钠者及脑出血接受克莱维地平或硝普钠者,治疗前后收缩压标准差无显著差异。
- 脑出血接受尼卡地平者治疗后收缩压标准差显著升高(13.1 vs 14.2,p=0.0032)。
证据类型、等级与局限
- 证据类型为基于MIMIC-IV数据库的观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,结果强调需要优化治疗干预以减少急性卒中患者的收缩压波动。
- 观察性研究显示静脉降压药物降低收缩压但不减少收缩压波动,收缩压波动与院内死亡相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: We performed an analysis of a large intensive care unit electronic database to provide preliminary estimates of various blood pressure parameters in patients with acute stroke receiving intravenous (IV) antihypertensive medication and determine the relationship with in-hospital outcomes.
METHODS: We identified the relationship between pre-treatment and post-treatment systolic blood pressure (SBP) and heart rate (HR)-related variables and in-hospital mortality and acute kidney injury in patients with acute stroke receiving IV clevidipine, nicardipine, or nitroprusside using data provided in the Medical Information Mart for Intensive Care (MIMIC) IV database.
RESULTS: A total of 1830 patients were treated with IV clevidipine (n = 64), nicardipine (n = 1623), or nitroprusside (n = 143). The standard deviations [SDs] of pre-treatment SBP (16.3 vs. 13.7, p ≤ 0.001) and post-treatment SBP (15.4 vs. 14.4, p = 0.004) were higher in patients who died compared with those who survived, particularly in patients with intracerebral hemorrhage (ICH). The mean SBP was significantly lower post treatment compared with pre-treatment values for clevidipine (130.7 mm Hg vs. 142.5 mm Hg, p = 0.006), nicardipine (132.8 mm Hg vs. 141.6 mm Hg, p ≤ 0.001), and nitroprusside (126.2 mm Hg vs. 139.6 mm Hg, p ≤ 0.001). There were no differences in mean SDs post treatment compared with pre-treatment values for clevidipine (14.5 vs. 13.5, p = 0.407), nicardipine (14.2 vs. 14.6, p = 0.142), and nitroprusside (14.8 vs. 14.8, p = 0.997). The SDs of pre-treatment and post-treatment SBP were not significantly different in patients with ischemic stroke treated with IV clevidipine, nicardipine, or nitroprusside or for patients with ICH treated with IV clevidipine or nitroprusside. However, patients with ICH treated with IV nicardipine had a significantly higher SD of post-treatment SBP (13.1 vs. 14.2, p = 0.0032).
CONCLUSIONS: We found that SBP fluctuations were associated with in-hospital mortality in patients with acute stroke. IV antihypertensive medication reduced SBP but did not reduce SBP fluctuations in this observational study. Our results highlight the need for optimizing therapeutic interventions to reduce SBP fluctuations in patients with acute stroke.
参考来源
- Qureshi AI, Baskett WI, Lodhi A, et al. Assessment of Blood Pressure and Heart Rate Related Variables in Acute Stroke Patients Receiving Intravenous Antihypertensive Medication Infusions. Neurocrit Care. 2024. PMID: 38649651. doi:10.1007/s12028-024-01974-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。